Restoring apoptosis as a strategy for cancer gene therapy:: focus on p53 and mda-7

被引:72
作者
Lebedeva, IV
Su, ZZ
Sarkar, D
Fisher, PB
机构
[1] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA
关键词
gene therapy; programmed cell death; adenovirus; p53; ONYX-015; mda-7 (IL-24); clinical trials;
D O I
10.1016/S1044-579X(02)00134-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Understariding the molecular and genetic determinants of cancer will provide unique opportunities for developing rational and effective therapies. Malignant cells are frequently resistant to chemotherapy and radiation induced programmed cell death (apoptosis). This resistance can occur by mutations in the tumor suppressor gene p53. Strategies designed to replace this defective tumor suppressor protein, as well as forced expression of a novel cancer specific apoptosis inducing gene, melanoma differentiation associated gene-7 (mda-7), offer promise for restoring apoptosis in tumor cells. Conditional-replicating viruses that selectively induce cytolysis in tumor cells provides an additional means of targeting cancer cells for destruction. Although these approaches represent works in progress, future refinements will in all likelihood result in the next generation of cancer therapies. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:169 / 178
页数:10
相关论文
共 124 条
[11]  
Brown JM, 1999, CANCER RES, V59, P1391
[12]   Gene therapy for the treatment of cancer [J].
Buchsbaum, DJ ;
Curiel, DT .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (04) :275-288
[13]   A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer [J].
Buller, RE ;
Runnebaum, IB ;
Karlan, BY ;
Horowitz, JA ;
Shahin, M ;
Buekers, T ;
Petrauskas, S ;
Kreienberg, R ;
Slamon, D ;
Pegram, M .
CANCER GENE THERAPY, 2002, 9 (07) :553-566
[14]   Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 [J].
Buller, RE ;
Shahin, MS ;
Horowitz, JA ;
Runnebaum, IB ;
Mahavni, V ;
Petrauskas, S ;
Kreienberg, R ;
Karlan, B ;
Slamon, D ;
Pegram, M .
CANCER GENE THERAPY, 2002, 9 (07) :567-572
[15]   Checkpoints: How to activate p53 [J].
Caspari, T .
CURRENT BIOLOGY, 2000, 10 (08) :R315-R317
[16]   The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24 [J].
Caudell, EG ;
Mumm, JB ;
Poindexter, N ;
Ekmekcioglu, S ;
Mhashilkar, AM ;
Yang, XHH ;
Retter, MW ;
Hill, P ;
Chada, S ;
Grimm, EA .
JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6041-6046
[17]   GENETIC MECHANISMS OF TUMOR SUPPRESSION BY THE HUMAN P53 GENE [J].
CHEN, PL ;
CHEN, YM ;
BOOKSTEIN, R ;
LEE, WH .
SCIENCE, 1990, 250 (4987) :1576-1580
[18]   p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells [J].
Chen, XB ;
Ko, LJ ;
Jayaraman, L ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (19) :2438-2451
[19]  
Clayman GL, 1999, CLIN CANCER RES, V5, P1715
[20]   Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma [J].
Clayman, GL ;
El-Naggar, AK ;
Lippman, SM ;
Henderson, YC ;
Frederick, M ;
Merritt, JA ;
Zumstein, LA ;
Timmons, TM ;
Liu, TJ ;
Ginsberg, L ;
Roth, JA ;
Hong, WK ;
Bruso, P ;
Goepfert, H .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2221-2232